A new resource to help identify cancer-related immune targets.
Official title: The immunoPeptidoGenomic (iPepGen) informatics resource forimmuno-oncology research
Funded at University of Minnesota · NIH-11099677 · Data updated 2026-11-12
This study is creating a helpful tool called iPepGen that will make it easier for cancer researchers to find special markers in tumors that can help the immune system fight cancer, and it will also provide training to help them use this tool effectively.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $386,780 |
| NIH project number | 5U01CA288888-02 |
| Project ID | NIH-11099677 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancer who may benefit from immunotherapy targeting neoantigens.
✕Less likely to help
Patients with non-cancerous conditions or those not eligible for immunotherapy may not receive any benefit from this research.
What this research studies
This research focuses on developing an informatics resource called iPepGen, which will assist cancer researchers in identifying neoantigens—unique immune targets that arise from tumor-specific changes in DNA and RNA. By utilizing next-generation sequencing (NGS) data and advanced mass spectrometry techniques, the project aims to create accessible workflows for predicting and confirming these neoantigens. This resource will also provide training materials to help researchers effectively use the tools for their studies in immuno-oncology.
Why it matters
Potential benefit: If successful, this research could enhance the development of personalized cancer therapies by improving the identification of immune targets for treatment.
How similar studies have gone: Other research has shown success in using bioinformatics approaches to identify neoantigens, indicating that this methodology has potential for impactful results.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Griffin, Timothy J. — University of Minnesota
- Study coordinator: Griffin, Timothy J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.